A review of telbivudine for the management of chronic hepatitis B virus infection

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 10, 2008, Pages 1351-1361

  Lui, Yanni Y N ^a   Chan, Henry L Y ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adefovir; Dipivoxil; Entecavir; Hepatitis B; IFN; Lamivudine; Pharmacokinetics; Telbivudine; Treatment

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B(E) ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; LAMIVUDINE; PEGINTERFERON; PLACEBO; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; CREATINE KINASE BLOOD LEVEL; DNA SYNTHESIS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART ARRHYTHMIA; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUSCLE DISEASE; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; SEROCONVERSION; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE; VIRUS RESISTANCE;

ADENINE; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; NUCLEOSIDES; PHOSPHONIC ACIDS; PYRIMIDINONES;

HEPATITIS B VIRUS;

EID: 55049100587     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.10.1351     Document Type: Review

References (59)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-41
2. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; In press
3. Chan HLY, Sung JJY. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006;26:153-61
4. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994;23:437-55
5. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
6. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86
7. Chen G, Lin W, Shen F, et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006;101:1797-803
8. Chan HLY, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of heparocellular carcinoma. J Clin Oncol 2008;26:177-82
9. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31
10. Eun JR, Jang BI, Kim TN, et al. The effect of lamivudine on preventing hepatocellular carcinoma in chronic hepatitis B: a retrospective study of 2518 patients [abstract]. Hepatology 2006;44:550A
11. Sung JJY, Tsoi KK, Wong VWS, et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepato-cellular carcinoma. Aliment Pharmacol Ther 2008 Jul 24. [Epub ahead of print]
12. Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-91
13. Chan HLY, Wong VW, Tse CH, et al. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B. Aliment Pharmacol Ther 2007;25:891-8
14. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:283-90
15. Bryant ML, Bridges EG, Placidi L, et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001;45:229-35
16. Standring DN, Bridges EG, Placidi L, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001;12(Suppl 1):119-29
17. Zhou XJ, Lim SG, Lloyd DM, et al. Pharmacokinetics of telbivudine following administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacokinetic implications. Antimicrob Agents Chemother 2006;50:874-9
18. Zhou XJ, Lloyd DM, Chao GC, et al. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J Clin Pharmacol 2006;46:275-81
19. Hu P, Jiang J, Wang H, et al. Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects. J Clin Pharmacol 2006;46:999-1007
20. Zhou XJ, Marbury TC, Alcorn HW, et al. Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment. Antimicrob Agents Chemother 2006;50:1721-6
21. Zhou XJ, Swan S, Smith WB, et al. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. Antimicrob Agents Chemother 2007;51:4231-5
22. Zhou XJ, Fielman BA, Lloyd DM, et al. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob Agents Chemother 2006;50:2309-15
23. Zhou XJ, Pietropaolo K, Becker M, et al. Absence of pharmacokinetic drug-drug interaction between telbivudine and tenofovir [abstract]. Gastroenterology 2007;132(Suppl 2):A766
24. Zhou XJ, Fielman B, Dubuc-Patrick G, et al. Absence of pharmacokinetic drug-drug interaction between telbivudine and peginterferon alpha-2a or cyclosporine in healthy subjects [abstract]. J Hepatol 2006;44(Suppl 2):S194
25. Bridges EG. Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity or carcinogenicity [abstract]. J Hepatol 2006;44(Suppl 2):S147
26. Lai CL, Lim SG, Brown NA, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004;40:719-26
27. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-36
28. Lai CL, Leung N, Teo EK, et al. Phase IIb extended-treatment trial of telbivudine (LdT) vs lamivudine vs combination treatment in hepatitis B patients: two-year results [abstract]. Gastroenterology 2005;128(Suppl 2):A-692
29. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88
30. Lai CL, Gane E, Hsu CW, et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine [abstract]. Hepatology 2006;44(Suppl 1):222A
31. Di Bisceglie AM, Lai CL, Gane E, et al. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients [abstract]. Hepatology 2006;44:230A
32. Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008;47:447-54
33. Safadi R, Xie Q, Chen Y, et al. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: results of the primary analysis at week 24 [abstract]. J Hepatol 2007;46(Suppl):S196-7
34. Chan HLY, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007;147:745-54
35. Zhang XS, Jin R, Zhang SB, et al. Clinical features of adverse reactions associated with telbivadine. World J Gastroenterol 2008;14:3549-53
36. Chan HLY, Hui AY, Wong VWS, et al. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005;41:1357-64
37. Sung JJY, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005;128:1890-7
38. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-7
39. Tenney DJ, Pokornowski KA, Rose RE, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance [abstract]. Hepatol Int 2008;2:A88
40. Sung JJY, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefavir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008;48:728-35
41. Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007;133:1445-51
42. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008;48:99-108
43. Chan HLY, Leung NWY, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-α2b and lamivudine with lamivudine alone. Ann Intern Med 2005;142:240-50
44. Chan HLY, Wong VWS, Chim AML, et al. Virological response to different combination regimes of peginterferon alfa-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. Antiviral Ther 2007;12:815-23
45. Risk of peripheral neuropathy in patients treated with telbivudine (SEBIVO®) in combination with interferon. Norvartis, 2008. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/ sebivo_hpc-cps-eng.pdf
46. Van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420-4
47. Chan HLY, Wong ML, Hui AY, et al. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World J Gastroenterol 2003;9:2695-7
48. Chan HLY, Wong VWS, Tse AML, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007;5:1462-8
49. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004;19:1276-82
50. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16
51. Hadziyannis SJ, Tassopouios NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7
52. Marcellin P, Chang TT, Lim SG, et al. long-term efficacy and safety of adefovir dioivoxiol for the treatment of HbeAg-positive chronic hepatitis B (CHB) patients in study GS-98-437 [abstract 969]. 57th AASLD; 2006 October 27-31; Boston, MA
53. Hadziyannis SJ, Tassopouios NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B up to 5 years. Gastroenterology 2006;131:1743-51
54. Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007;45:307-13
55. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10
56. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
57. Heathcote J, George J, Gordon S, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103) [abstract]. J Hepatol 2008;48:S32
58. Marcellin P, Jacobson I, Habersetzer F, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102) [abstract]. J Hepatol 2008;48:S26
59. Van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-5